Natural anticoagulant proteins in the regulation of autoimmunity: Potential role of protein S

被引:9
作者
Anderson, HA [1 ]
Shacter, E [1 ]
机构
[1] Ctr Drug Evaluat & Res, Food & Drug Adm, Biochem Lab, Div Therapeut Prot, Bethesda, MD 20892 USA
关键词
protein S; apoptosis; phagocytosis; autoimmunity; anticoagulant protein; coagulation; protein C; activated protein C;
D O I
10.2174/1381612043452839
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Autoimmunity results when the immune system fails to distinguish between self and non-self factors in the body. The cellular and biochemical mechanisms that underlie development of autoimmunity are only partly understood. One current theory is that autoimmunity can result when there is a failure to clear dying cells from a tissue before they undergo lysis of the plasma membrane. That is, cells that die by apoptosis are thought to be cleared from a tissue by neighboring phagocytic cells, such as macrophages, before the cells have lost their plasma membrane integrity. This rapid removal of early apoptotic cells is thought to prevent induction of an inflammatory response to intracellular macromolecules, thereby allowing for an immunologically silent removal of the dying cells. Hence, any factor or condition that inhibits phagocytosis of early apoptotic cells may trigger or promote an autoimmune response to intracellular components. Depletion of factors required for the efficient phagocytosis of dying cells would have a similar outcome. The recent discovery that the natural anticoagulant protein S is required for efficient uptake of apoptotic cells (Anderson, H.A., Maylock, C.A., Williams, J.A., Paweletz, C.P., Shu, H., and Shacter, E. (2003) Nature Immunology 4, 87-91) reveals a potential new linkage between autoimmunity and coagulation systems. This article will review the dual roles of protein S as an anticoagulant and in regulating phagocytosis of apoptotic cells, with emphasis on exposing a possible novel role in regulating autoimmunity.
引用
收藏
页码:929 / 937
页数:9
相关论文
共 98 条
[91]  
ten Cate H, 2001, CRIT CARE MED, V29, pS51
[92]   Hypercoagulability syndromes [J].
Thomas, RH .
ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (20) :2433-2439
[93]   Immunosuppressive effects of apoptotic cells [J].
Voll, RE ;
Herrmann, M ;
Roth, EA ;
Stach, C ;
Kalden, JR ;
Girkontaite, I .
NATURE, 1997, 390 (6658) :350-351
[94]   REGULATION OF BLOOD-COAGULATION BY THE PROTEIN-C SYSTEM [J].
WALKER, FJ ;
FAY, PJ .
FASEB JOURNAL, 1992, 6 (08) :2561-2567
[95]   High-dose a randomized antithrombin III in severe sepsis -: A randomized controlled trial [J].
Warren, BL ;
Eid, A ;
Singer, P ;
Pillay, SS ;
Carl, P ;
Novak, I ;
Chalupa, P ;
Atherstone, A ;
Pénzes, I ;
Kübler, A ;
Knaub, S ;
Keinecke, HO ;
Heinrichs, H ;
Schindel, F ;
Juers, M ;
Bone, RC ;
Opal, SM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (15) :1869-1878
[96]   Vitamin K-dependent protein S localizing complement regulator C4b-binding protein to the surface of apoptotic cells [J].
Webb, JH ;
Blom, AM ;
Dahlbäck, B .
JOURNAL OF IMMUNOLOGY, 2002, 169 (05) :2580-2586
[97]   Perspective: Treating sepsis. [J].
Wenzel, RP .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) :966-967
[98]   Treating severe sepsis with drotrecogin alfa (activated) [J].
Wyncoll, D .
HOSPITAL MEDICINE, 2003, 64 (03) :168-172